Andishe Attarbaschi

TL;DR: This study provides a comprehensive analysis of the MLL recombinome in acute leukemia and demonstrates that the establishment of patient-specific chromosomal fusion sites allows the design of specific PCR primers for minimal residual disease analyses for all patients.

TL;DR: Age, Ph(+), and AML therapy were predictors for poor outcome, and MPAL is confirmed to be a poor-risk disease and Adults and Ph(+) patients should be considered for transplantation in first remission.

TL;DR: It is concluded that, for patients with PGR in the large subgroup of precursor B-cell ALL, dexamethasone especially reduced the incidence of better salvageable relapses, resulting in inferior survival after relapse.

TL;DR: These expert opinion-based definitions will allow reliable comparisons of frequencies and severities of acute toxic effects across treatment protocols, and facilitate international research on cause, guidelines for treatment adaptation, preventive strategies, and development of consensus algorithms for reporting on acute lymphoblastic leukaemia treatment.

TL;DR: It is shown that PAX5 rearrangements occur at an incidence of about 2.5% of B-cell precursor ALL, and identification of several novel PAX5 partner genes, including POM121, BRD1, DACH1, HIPK1 and JAK2 brings the number of distinct PAX5 in-frame fusions to at least 12.